Zedira is a clinical-stage biotech company specializing in the enzyme class of transglutaminases. The Darmstadt, Germany-based enterprise develops small-molecule drug candidates. In doing so, the company is working at the cutting edge of drug discovery designing compounds that block dysregulated enzymatic activity of transglutaminases.      

Drug candidates developed by Zedira:     


Proof of concept was shown in a Phase 2a study on celiac disease     
  • All dose groups met the primary endpoint
  • Placebo-like safety profile
  • First-in-class compound
  • Validation of a transglutaminase as a druggable target for the first time

Partnering opportunity:     

Licensed to Takeda Pharmaceuticals and Dr. Falk Pharma


  • Novel 2nd generation tissue transglutaminase inhibitor
  • Improved oral bioavailability
  • Reversible-acting warhead
  • Rodent pharmacokinetic and efficacy data available

Seeking licensee(s)/development partner(s)      

Preferred indications include     
  • Diabetic nephropathy
  • Idiopathic pulmonary fibrosis
  • Mesothelioma cancer
  • Liver fibrosis


    • First-in-class “safe” anticoagulant
    • Direct-acting irreversible Factor XIIIa (F13a) inhibitor
    • Proof-of-principle in rabbit model shown

    Seeking licensee(s)/development partner(s)      

    Preferred indications include     
  • Hemodialysis
  • Acute kidney injury
  • Acute lung injury

    Zedira is open to considering alliances and agreements with the pharmaceutical industry. Please do not hesitate to contact us. Zedira’s management team, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal:     
    Phone: +49 6151 66628-0 or
    E-mail: contact@zedira.com